1. Introduction {#sec1}
===============

Psoriasis is a common inflammatory disease affecting more than 25 million people in North America and Europe. It is associated with arthritis, myopathy, enteropathy, spondylotic joint disease, and atopic dermatitis. This disease is characterized by well-demarcated lesions on the skin of the elbows, knees, and scalp. It is an autoimmune disease triggered by an activated cellular immune system resulting from a combination of genetic and environmental factors. It is also frequently inherited and is passed from one generation to the next \[[@B1]\].

Many factors trigger psoriasis, including bacterial pharyngitis, stress, and various medications (e.g., lithium and *β*-blockers). Perturbation of epidermal keratinocytes is considered an activating signal in psoriasis \[[@B2]\], and in regions with psoriasis lesions, keratinocyte proliferation is increased along with inflammation and angiogenesis \[[@B3]\]. Recent studies have reported that the interaction between T-cells and keratinocytes gives rise to a cytokine soup dominated by Th1-type and Th17-type cytokines such as interleukin- (IL-) 12, IL-17, interferon- (IFN-) *γ*, and tumor necrosis factor (TNF) \[[@B4]\]. In addition, keratinocytes stimulated with IL-20 upregulate a variety of inflammatory genes, including monocyte chemotactic protein-1 (MCP-1) and myeloid-related protein-14 (MRP-14) \[[@B5], [@B6]\].

Some genetic studies have reported a strong association between psoriasis and human leukocyte antigen- (HLA-) C, particularly with the HLA-Cw0602 allele. Individuals who are homozygous have a 2.5-fold higher risk of developing psoriasis than those who are heterozygous \[[@B7]\]. Moreover, a genomewide association study revealed that polymorphisms in genes related to IL-23 and nuclear transcription factor *κ*B (NF*κ*B) signaling are associated with psoriasis \[[@B8]\]. TNF is currently considered a major target in psoriasis pathogenesis, because much higher levels of TNF are found in lesional skin than in normal skin \[[@B9]\]. Treatment with TNF antagonists elicits a response in patients with psoriasis. However, despite the success of anti-TNF-*α* therapies, the involvement of TNF-*α* in disease pathogenesis is not yet fully understood. Furthermore, these drugs have clinical nonresponse rates that range from 20% to 50% in patients with psoriasis \[[@B10]\]. Therefore, there is a need for new and effective drug targets and compounds.

New research initiatives have been undertaken to collect high-throughput mRNA expression and protein-protein interaction (PPI) data from different organisms. This important source of biological information has been effectively employed in the search for new drugs \[[@B11]\]. Systematic analysis using bioinformatics has enabled researchers to extract and manipulate biological information with the goal of understanding the pathogenesis of disease. In particular, the combined analysis of gene expression and PPI may help identify candidates that are potential therapeutic targets. Recent studies analyzing protein interaction networks have been carried out in *Saccharomyces cerevisiae*and *Caenorhabditis elegans* \[[@B12], [@B13]\]; such studies have confirmed that topological metrics of protein interaction networks are useful for predicting essential target proteins. These studies have also been expanded to organisms of medical importance, such as the malaria parasite \[[@B14]\], as a starting point for the discovery of new drug targets. In humans, the analysis of PPIs has also been useful in detecting important proteins, such as hub proteins, when the interactions were predicted using a homologous approach \[[@B15]\].

To better understand the pathogenesis of psoriasis and to identify potential therapeutic targets, we performed a microarray analysis comparing lesional and nonlesional psoriatic skin and a protein interaction network analysis that was constructed using differentially expressed genes obtained from the microarray data. We identified potential therapeutic or drug target candidates by analyzing the protein interaction network with the metrics of degree and centrality. We then selected the enzymes from the candidates and detected nonsynonymous single-nucleotide polymorphisms (SNPs) in the enzyme genes that could cause structural changes in the proteins. These putative enzyme targets are a starting point for the discovery of new psoriasis drugs.

2. Materials and Methods {#sec2}
========================

2.1. Microarray Analysis Related to Psoriasis {#sec2.1}
---------------------------------------------

Microarray data from psoriasis patients were downloaded from Gene Expression Omnibus (GEO), which is a public database of centrally archived raw microarray data \[[@B16]\]. We used 2 microarray datasets (GDS2518 and GDS3539) generated using Affymetrix human genome microarrays, which have more than 4 million gene expression measurements. The GDS2518 dataset contained transcriptome data of lesional and nonlesional skin from 13 patients with plaque-type psoriasis \[[@B17]\]. The GDS3539 dataset contained similar data from 33 patients \[[@B18]\]. In order to identify genes that are differentially expressed in psoriasis patients, we compared lesional and nonlesional skin data to microarray datasets.

2.2. Identification of Differentially Expressed Genes from Transcriptome {#sec2.2}
------------------------------------------------------------------------

We removed probe redundancy because 1 gene has several probes on a single microarray chip. After removing the redundancy, the average expression profiles were calculated for the probe clusters having multiple expression profiles. From each of the given microarray datasets, we obtained differentially expressed genes (DEGs) by unpaired two class analysis (Sigma = 2.4, *Q*-value = 0.0001) by using significance analysis for microarray (SAM) \[[@B19]\]. We then combined the DEGs obtained from GDS2518 and GDS3539.

2.3. PPI Resources {#sec2.3}
------------------

Predictions of PPI have been applied in various studies in order to understand the mechanism of disease development, find key proteins related to species lethality, and search for drug targets between a host and pathogen \[[@B20]\]. PPI resources were assembled from a combination of several experimental protein interaction databases. The protein interaction resources include 6 databases: DIP \[[@B21]\], BIND \[[@B22]\], IntAct \[[@B23]\], MINT \[[@B24]\], HPRD \[[@B25]\], and BioGrid \[[@B26]\]. We performed a redundancy test to remove identical protein sequences from the interaction databases. The databases contain 116,773 proteins and 229,799 interactions.

2.4. Protein Network Prediction from the DEGs {#sec2.4}
---------------------------------------------

There are computational methods for predicting PPIs such as gene neighborhood \[[@B27]\], gene fusion \[[@B28]\], phylogenetic profile \[[@B29]\], and interolog \[[@B30]\]. In particular, the interolog approach is widely used to predict PPIs when the sequences of target proteins are known. In the interolog approach, the interaction of 2 query proteins is predicted when both have homologousproteins that are already known to interact \[[@B30]\]. A protein network of DEGs selected from the microarrays was predicted from homologous interactions. To find homologous interactions among the DEGs, we converted the DEGs to proteins, and we aligned these with proteins from the interaction resources using PSI-BLAST \[[@B31]\] with a minimal cutoff of 40% sequence identity, 70% length coverage, and an *E*-value of 0.0001.

2.5. Detection of Essential Proteins with Topological Metrics and Selecting for Enzymes {#sec2.5}
---------------------------------------------------------------------------------------

The protein network analysis has been applied to find essential proteins, such as hubs, that are related to a disease or biological pathway \[[@B11]\]. To find essential proteins, we performed a protein network analysis with topological metrics such as degree and betweenness centrality using Perl program. Proteins with a high number of interaction partners in the network were regarded as degree-based hubs. Proteins with many shortest paths between other proteins were regarded as betweenness-based hubs. Proteins that have high betweenness scores mainly exist in the middle of the protein network. If the protein is removed from the network, the proportion of unreachable protein pairs and the mean shortest path length between all pairs of reachable nodes are increased \[[@B32]\]. We selected the essential proteins that have the top 1% of total degree and 1% of total betweenness in the protein network as hubs. Finally, the proteins were filtered through the list of enzyme proteins stored in the ENZYME nomenclature database (<http://expasy.org/enzyme/>).

2.6. Structural Changes Induced by Nonsynonymous SNPs {#sec2.6}
-----------------------------------------------------

Nonsynonymous single-nucleotide polymorphisms (nsSNPs) have been implicated in various diseases; nsSNPs can alter protein function \[[@B33]\], destabilize core protein structure, and reduce protein solubility \[[@B34]\]. Because polymorphisms are an important genetic factor in psoriasis \[[@B7]\], we checked for nsSNPs in the selected enzymes using the dbSNP database (<http://www.ncbi.nlm.nih.gov/projects/SNP/>), and we predicted the structural changes in the enzymes caused by the nsSNPs through structure modeling and stability analysis. On the basis of homology modeling, three-dimensional structural models of the target enzymes were built using SWISS-MODEL \[[@B35]\]. The SWISS-MODEL program automatically provides an all-atom model using alignments between the query sequence and known homologous structures. For homology modeling, the known homologous structures of enzymes from the Protein Data Bank (PDB) (<http://www.pdb.org>/) were used as the structural templates. Further, the stability of the enzyme structure was checked using the CPUSAT program \[[@B36]\].

3. Results and Discussion {#sec3}
=========================

3.1. Psoriasis Microarray Coupled with SAM Analysis {#sec3.1}
---------------------------------------------------

We compared the microarray datasets GDS2518 and GDS3539 from regions with and without lesions in psoriasis patients. Using SAM (Sigma 2.6 cutoff value with a 0.0001 *Q*-value), 6,437 candidate genes were found, and 3,264 genes were upregulated while 3,173 genes were downregulated. Among the listed candidates were several distinct genes that have been known to be associated with psoriasis; these genes coded for TNF-*α*, IFN-*γ* receptor 1, IL-8, and IL-20 (data not shown). In this study, we used bioinformatic analyses in which several methods were integrated, including PPI and structure prediction, to detect novel candidate proteins except well-known genes.

3.2. Identification of Putative Therapeutic Candidates {#sec3.2}
------------------------------------------------------

There are several ways to obtain candidate genes for disease analysis, including cDNA microarray and proteomics approaches such as mass spectrometry. Although we could obtain many upregulated or downregulated genes in psoriasis using high-throughput omics approaches, it was very difficult to choose the important genes. However, PPI mapping can help find potential targets among these candidates. Recent studies have successfully applied this approach to discover drug targets using computational predictions of protein networks in the bacterium *Mycobacterium tuberculosis*and in humans \[[@B37]--[@B39]\]. Therefore, we predicted the protein interaction network of psoriasis-related proteins using homologous interaction prediction. We separately constructed 2 protein interaction networks using 3,264 upregulated genes and 3,173 downregulated genes in psoriasis. The protein interaction network constructed from the upregulated genes contained 1,310 proteins and 1,934 interactions, and the network constructed from the downregulated genes contained 985 proteins and 1,205 interactions, and they are shown in [Figure 1](#fig1){ref-type="fig"}. In order to find potential therapeutic candidates, we calculated the number of interacting partners (degree) \[[@B40]\] and betweenness centrality \[[@B41]\] for each protein. These 2 topological metrics have been shown to improve the detection of essential proteins in protein networks \[[@B42]\]. Betweenness centrality correlates more closely with essentiality than degree, thereby exposing critical nodes that usually belong to the group of scaffold proteins or proteins involved in cross-talk between signaling pathways. This metric has also been proposed in the new paradigm of network pharmacology as a good method for investigating potential drug targets \[[@B43]\]. In the protein network, we selected the top 1% of the degree and centrality rank as hub proteins because this cutoff value identifies the group with the highest probability to be an essential group of proteins. We chose 17 proteins in the upregulated gene protein interaction network and 15 proteins in the downregulated gene protein interaction network. The protein list and network properties are described in Tables [1](#tab1){ref-type="table"} and [2](#tab2){ref-type="table"}. We found the 5 enzymes by filtering the group of detected 32 proteins through the ENZYME nomenclature database. Among the upregulated genes, 4 enzymes were selected as putative targets: DNA helicase (RUVBL2), proteasome endopeptidase complex (PSMA2), non-specific protein-tyrosine kinase (ZAP70), and I-kappa-B kinase (IKBKE). From the downregulated genes, EGF receptor (EGFR) was selected.

3.3. Experimental Evidence of the Predicted Targets Related to Psoriasis {#sec3.3}
------------------------------------------------------------------------

The predicted enzymes were directly or indirectly related to psoriasis. The predicted enzymes have several significant features. IKBKE was already known as a psoriasis-related protein that is essential for the regulation of antiviral signaling and inflammatory pathways. TNF-*α*, which exists on upstream of IKBKE signaling pathway, has been used as a psoriasis drug target. TNF-*α* inhibitors such as etanercept are used for treating rheumatoid and psoriatic arthritis. The abnormal activation of T-cells is known to be a factor in the development of psoriasis. Therefore, T-cell infiltration and the inhibition of cytokines are the major modalities for the treatment of psoriasis \[[@B1]\].

ZAP70 plays a role in T-cell development and lymphocyte activation \[[@B44]\]. This enzyme, which is phosphorylated at tyrosine residues upon T-cell antigen receptor (TCR) stimulation, functions in the initial step of TCR-mediated signal transduction in combination with the Src family kinases Lck and Fyn \[[@B45]\]. Mutations in this enzyme cause selective T-cell defects and a severe combined immunodeficiency disease characterized by a selective absence of CD8-positive T-cells \[[@B46]\]. Furthermore, a significant change in ZAP70 expression was reported during the course of chronic lymphocytic leukemia \[[@B47]\].

We found EGFR, which plays a role in morphogenesis by modulating cell adhesion, as a downregulated target. EGFR promotes keratinocyte antimicrobial defenses in a differentiation-dependent manner. Ligands of the EGF family regulate autocrine keratinocyte proliferation, and IL-1 family cytokines have epithelial defense responses \[[@B48]\].

Two proteasome-related enzymes were also found among the upregulated target candidates. RUVBL2 is a DNA helicase that is essential for homologous recombination and DNA double-strand break repair. Recent research reported that the depletion of RUVBL2 leads to tumor growth arrest and that it is overexpressed in a majority of hepatocellular carcinomas \[[@B49]\]. Moreover, the enzyme levels are strictly controlled by a posttranslational mechanism involving proteasomal degradation of newly synthesized proteins \[[@B50]\]. PSMA2 is a proteasome subunit alpha type 2 and is a member of the peptidase T1A family. Proteasome-related enzymes may be valuable as therapeutic candidates since a proteasome blockade causes the overexpression of the suppressor of cytokine signaling (SOCS) 3protein, which inhibits the IFN-*α* response which are overexpressed in psoriasis \[[@B51]\].

This may be reasonable because these enzymes are important regulators in the mechanism of development of psoriasis. Although more information on the biological functions of these interesting enzymes is needed, they are potential candidates for future drug screening and therapeuticor drug target development.

3.4. Structural Stability Analysis of Enzymes Using nsSNPs {#sec3.4}
----------------------------------------------------------

We predicted the structural changes in ZAP70 caused by nsSNPs with structural modeling and stability analysis because mutations can cause selective T-cell defects \[[@B46]\]. Known homologous structures of ZAP70, PDB entries 1M61 and 1U59 (100% and 98.9% sequence identity), were used as structural templates. Currently, 19 nsSNPs in the dbSNP database have been reported to cause nonsense or missense changes in ZAP70. Using the CUPSAT program, we found 10 nsSNPs that cause unstable structural changes. The nsSNPs are shown in [Table 3](#tab3){ref-type="table"}. In particular, Val527Gly had the lowest unstable energy value. The native structure and changed structures are shown in [Figure 2](#fig2){ref-type="fig"}. Although there is no experimental evidence which shows that nsSNPs regulate the expression level in T-cells, stability analysis of the target structure can give us more biological information to understand the enzymatic mechanism and to evaluate the drug effect.

4. Conclusion {#sec4}
=============

In this study, we attempted to explore potential therapeutic candidates for psoriasis by utilizing bioinformatic methods. We have presented essential proteins from upregulated and downregulated genes in psoriasis; some of these findings have been supported by experimental evidence reported in the literature. Of particular interest are the predicted essential enzymes that are important proteins related to the pathogenesis of psoriasis; these enzymes can be explored as therapeutic or drug target candidates. Further studies should be conducted to determine the role of these candidate enzymes in psoriasis and to explore agonists of the upregulated candidates or antagonists of downregulated candidates as drug targets by exploiting the property of multiple targeting. These results will aid future drug discovery efforts, enabling drug development in a more timely and cost-effective manner.
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![Protein interaction networks constructed by DEGs in psoriasis. The node indicates protein and the edge indicates protein-protein interaction. The red nodes are essential enzymes predicted by topological metrics such as degree and betweenness centrality. (a) Protein interaction network constructed from genes upregulated in microarray data from regions with and without lesions in psoriasis patients. The network consisted of 1,310 proteins and 1,934 interactions. (b) Protein interaction network constructed from downregulated genes. The network consisted of 985 proteins and 1,205 interactions.](ER2011-826784.001){#fig1}

![Protein structure of ZAP70 and structural variations by nsSNPs. We predicted the structural changes in ZAP70 caused by nsSNPs through structural modeling and stability analysis because mutations can cause selective T-cell defects \[[@B46]\]. In order to predict the structure of ZAP70, we used PDB entries 1M61 and 1U59 as the structural templates, which have 100% and 98.9% sequence identity, respectively, which were found to be suitable structural templates. We found 19 nsSNPs from the dbSNP database that cause nonsense or missense changes in ZAP70. From these nsSNPs, 10 nsSNPs were found to lead to unstable structural changes by using CUPSAT. In particular, Val527Gly had the lowest unstable energy value (Predicted ΔΔ*G*: −4.09). The red region shows the location of Val527Gly in the middle of the alpha-helix structure.](ER2011-826784.002){#fig2}

###### 

Selected hub proteins in the protein interaction network constructed from upregulated genes.

  *Gene symbol*   *Refseq ID*          *Full name (enzyme number)*                                                        *Topological metrics*
  --------------- -------------------- ---------------------------------------------------------------------------------- ------------------------
  CDKN1A          NP_000380.1          Cyclin dependent kinase inhibitor 1A                                               centrality: 64419
  **RUVBL2**      **NP_006657.1**      **RuvB like 2 (3.6.4.12: DNA helicase)**                                           **centrality: 50925**
  COPS6           NP_006824.2          COP9 constitutive photomorphogenic homolog subunit 6                               centrality:60596
  EWSR1           NP_001156757.1       Ewing sarcoma breakpoint region 1                                                  centrality: 62682
  FTSJ1           NP_036412.1          FtsJ homolog 1                                                                     degree: 27
  SFN             NP_006133.1          14-3-3 sigma                                                                       centrality: 50372
  GRB2            NP_002077.1          Grb2                                                                               centrality: 397096
  CCDC85C         NP_001138467.1       C14orf65 protein                                                                   centrality: 76862
  EIF6            NP_002203.1          Eukaryotic translation initiation factor 6                                         centrality: 61909
  ARF6            NP_001654.1          ADP ribosylation factor 6                                                          centrality: 45220
  NFKB1           NP_001158884.1       NFKB1                                                                              degree: 18
  PCNA            NP_002583.1          Proliferating cell nuclear antigen                                                 centrality: 46316
  PINX1           NP_060354.4          Pin2 interacting protein X1                                                        centrality: 51027
  **PSMA2**       **NP_002778.1**      **Proteasome subunit alpha type 2 (3.4.25.1: Proteasome endopeptidase complex)**   **degree: 17**
  VDAC1           NP_003365.1          VDAC1                                                                              degree: 18
  **ZAP70**       **NP_001070.2**      **ZAP70 (2.7.10.2: Nonspecific protein-tyrosine kinase)**                          **centrality: 50140**
  **IKBKE**       **NP_001180250.1**   **IKKE (2.7.11.10: I-kappa-B kinase)**                                             **centrality: 412760**

###### 

Selected hub proteins in the protein interaction network constructed from downregulatedgenes.

  *Gene symbol*   *Refseq ID*       *Full name (enzyme number)*                                     *Topological metrics*
  --------------- ----------------- --------------------------------------------------------------- -----------------------
  EIF1B           NP_005866.1       Translation factor sui1 homolog                                 centrality: 41540
  RNPS1           NP_006702.1       RNA binding protein S1, serine-rich domain                      degree: 21
  **EGFR**        **NP_005219.2**   **EGF receptor (2.7.10.1: Receptor protein-tyrosine kinase)**   **centrality: 83945**
  NINL            NP_079452.3       KIAA0980 protein                                                centrality: 53502
  HTT             NP_002102.4       Huntingtin                                                      centrality: 99972
  HMGB1           NP_002119.1       High mobility group box 1                                       centrality: 43032
  APP             NP_000475.1       Amyloid beta A4 protein                                         centrality: 51716
  RIF1            NP_001171134.1    Rap1 interacting factor 1                                       degree: 17
  PLSCR4          NP_001121778.1    Phospholipid scramblase 4                                       centrality: 60954
  BCL6            NP_001124317.1    B cell lymphoma 6 protein                                       degree: 18
  TBP             NP_001165556.1    TATA box binding protein                                        centrality: 40738
  SUMO1           NP_001005781.1    SMT3 suppressor of mif two 3 homolog 1                          degree: 21
  UNC119B         NP_001074002.1    Unc-119 homolog B                                               centrality: 42366
  NCOR1           NP_001177367.1    Nuclear receptor corepressor 1                                  degree: 16
  UTP14C          NP_067677.4       UTP14, U3 small nucleolarribonucleoprotein, homolog C           centrality: 60679

###### 

Nonsynonymous SNPs of ZAP70.

  *rsNumber*        *DNA substitution*   *Amino-acid substitution*   *Overall stability*   *Predicted ΔΔG (kcal/mol)*
  ----------------- -------------------- --------------------------- --------------------- ----------------------------
  **rs56077145**    **106C \> G**        **Leu36Val**                **Destabilising**     **−1.03**
  rs113994172       239C \> A            Pro80Gln                    Stabilising           0.82
  rs56264206        308A \> T            Asn103Ile                   Stabilising           0.71
  **rs55845489**    **309C \> A**        **Asn103Lys**               **Destabilising**     **−0.36**
  rs55679020        311G \> C            Arg104Pro                   Stabilising           0.11
  rs111771234       550T \> A            Phe115Ile                   Stabilising           0.67
  **rs55964305**    **524G \> T**        **Arg175Leu**               **Destabilising**     **−0.67**
  rs56403250        572C \> T            Pro191Leu                   Stabilising           0.08
  **rs76059124**    **653C \> T**        **Ala218Val**               **Destabilising**     **−1.86**
  **rs113310375**   **1274T \> C**       **Val356Ala**               **Destabilising**     **−2.01**
  **rs113994174**   **1393C \> T**       **Arg465Cys**               **Destabilising**     **−0.81**
  **rs56059280**    **1468G \> A**       **Asp490Asn**               **Destabilising**     **−0.29**
  **rs104893674**   **1554C \> A**       **Ser518Arg**               **Destabilising**     **−0.56**
  rs56189815        1568G \> T           Trp523Leu                   Stabilising           3.36
  **rs56146954**    **1580T \> G**       **Val527Gly**               **Destabilising**     **−4.09**
  rs113994175       1714A \>T            Met572Leu                   Stabilising           0.17
  rs55803111        1781G \> A           Arg594Gln                   Stabilising           1.11
  **rs56326640**    **1783G \> T**       **Ala595Ser**               **Destabilising**     **−0.36**
  rs56250717        1826G \> A           Gly609Asp                   ---                   ---
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